Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029857 | 0.80 | ADORA2A (0.43) | ADORA2AADORA1PDK1PDK2PDK3 | |
| SCHEMBL2564796 | 0.79 | ADORA2A (0.42) | ADORA2AADORA1PDK1DYRK1ALMNA | |
| SCHEMBL7655789 | 0.79 | DYRK1A (0.42) | ADORA2AADORA1PDK1PDK2PDK3 | |
| SCHEMBL10012874 | 0.79 | ADORA2A (0.39) | ADORA2AADORA1PDK1PDK2PDK3 | |
| SCHEMBL4016987 | 0.76 | MAPT (0.39) | ADORA2AADORA1PDK1DYRK1AMAPK1 | |
| SCHEMBL14004647 | 0.76 | ADORA2A (0.37) | ADORA2AADORA1PDK1PDK2PDK3 | |
| SCHEMBL3126517 | 0.76 | ADORA2A (0.42) | ADORA2AADORA1DYRK1AMAPK1PRKCI | |
| 7-Deazaxanthine SCHEMBL1014230 | 0.75 | DYRK1A (0.40) | ADORA2AADORA1DYRK1AMAPK1PRKCI | |
| SCHEMBL166205 | 0.74 | TRPA1 (0.38) | DYRK1AMAPK1MEN1KMT2AMAPT | |
| SCHEMBL7016051 | 0.72 | LRRK2 (0.42) | PDK1MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3955929-B1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | UNIV LIEGE (BE) | 2024-05-15 | — | — | EP | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | Université de Liège (BE) | 2022-09-06 | — | — | US | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| CN-113329753-A | Novel pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, contaminations and dirt | 列日大学 | 2021-08-31 | — | — | CN | disclosed |
| US-20210061804-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | Université de Liège (BE) | 2021-03-04 | — | — | US | disclosed |
| WO-2020212553-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2020-10-22 | — | — | WO | disclosed |
| CN-111386271-A | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019158655-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITE DE LIEGE (BE) | 2019-08-22 | — | — | WO | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061804-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | TYMP, TYMS, UMPS | ADORA2A 147/4885ADORA1 120/4885PDK1 1088/4885 |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | ADORA2A 288/4885ADORA1 379/4885PDK1 2578/4885 |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | PIGS, TYMP, TYMS | ADORA2A 288/4885ADORA1 379/4885PDK1 2578/4885 |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | ADORA2A 1933/4885ADORA1 3035/4885PDK1 389/4885 |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | TYMP, TYMS, UMPS | ADORA2A 147/4885ADORA1 120/4885PDK1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.